Core Viewpoint - Kanghong Pharmaceutical's eye injection, Kangbaxip, has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, reflecting recognition of its innovation and clinical value by the National Healthcare Security Administration [1] Group 1: Product Inclusion - Kangbaxip is the only domestic innovative drug covering four major indications for retinal diseases in the current catalog [1] - The inclusion in the regular catalog management will enhance the stability and accessibility of medication for patients [1] Group 2: Ongoing Clinical Trials - The company is actively conducting Phase III clinical trials for high-dose Kangbaxip [1] - Clinical trials for gene therapy drugs KH631 and KH658 are being carried out in both China and the United States [1] - The aim is to benefit more patients through high-quality innovation [1]

Core Insights - Hansoh Pharmaceutical (03692) announced that its innovative drug Amivantamab has successfully added two new indications to the 2025 National Medical Insurance Directory, which will be implemented on January 1, 2026 [1][2] Group 1: New Indications for Amivantamab - Amivantamab (brand name: 阿美乐) has received approval for two new indications for the treatment of adult non-small cell lung cancer (NSCLC) patients with specific EGFR mutations [1] - The new indications include treatment for patients who have previously undergone surgical resection and for those with locally advanced, unresectable NSCLC who have not shown disease progression during or after platinum-based chemotherapy [1] Group 2: Renewal of Other Drugs in the National Medical Insurance Directory - The drug Pemigatinib (brand name: 圣罗莱) has had its two indications renewed for inclusion in the 2025 National Medical Insurance Directory, specifically for treating anemia caused by chronic kidney disease [2] - The drug Adefovir Dipivoxil (brand name: 恒沐) has also been renewed for chronic hepatitis B treatment in adult patients [2] - Other innovative drugs such as Fluoromethylphenyl (brand name: 豪森昕福), Pegylated Liraglutide (brand name: 孚来美), and Inotuzumab Ozogamicin (brand name: 昕越) are currently under the National Medical Insurance Directory agreement until December 31, 2026 [2]

银诺医药-B(02591)发布公告，集团核心产品(即依苏帕格鲁肽α)已成功纳入中国最新版《国家医保药品 目录》(2025年版)，用于治疗2型糖尿病("T2D")适应症。最新版《国家医保药品目录》将于2026年1月1 日正式生效。 ...

格隆汇12月7日丨君实生物(01877.HK)公告，公司产品特瑞普利单抗注射液(商品名：拓益，产品代号： JS001)2项新增适应症、昂戈瑞西单抗注射液(商品名：君适达，产品代号：JS002)成功纳入《国家基本 医疗保险、生育保险和工伤保险药品目录(2025年)》("国家医保目录")乙类范围。新版国家医保目录将 于2026年1月1日起正式实施。 本次拓益新增适应症和君适达纳入国家医保目录，体现了国家医疗保障局("国家医保局")对上述药物的 临床价值、患者获益、创新程度等方面的认可，凸显了国家对本土创新药企的药物研发和产业化工作的 重视和支持。 公司商业化产品均已纳入国家医保目录，有助于进一步提高在患者中的可负担性和可及性，有利于进一 步推动商业化产品的市场推广、提升销售规模，对公司的长期经营发展具有积极影响。公司将积极配合 推进医保政策落地，持续推进医院准入工作、拓展核心市场及广阔市场的覆盖，以期不断提升患者的用 药可及性。医保报销细则等相关信息，需以国家医保局等相关政府部门公示信息为准。敬请广大投资者 谨慎投资，注意投资风险。 截至本公告日期，公司4款商业化产品拓益、阿达木单抗注射液(商品名：君迈康，产品代 ...

2025年国家医保目录、商保创新药目录将于2026年1月1日起执行。其中，2025年国家医保目录的具体医保支付标准、医保报 销细则、谈判药品的协议有效期等信息，须以国家医疗保障局等相关政府部门公示信息为准。 复星医药（600196）(02196)发布公告，根据2025年12月7日国家医疗保障局、人力资源社会保障部发布的《国家基本医疗保 险、生育保险和工伤保险药品目录(2025年)》(以下简称"2025年国家医保目录")以及首次发布的《商业健康保险创新药品目录 (2025年)》(以下简称"商保创新药目录")，上海复星医药(集团)股份有限公司及控股子公司/单位(以下简称"本集团")多款已上市 产品获首次纳入或涉及备注信息调整，现将有关情况公告如下： | 情形 | 药品名称 | 中国境内 | 中国境内 | | --- | --- | --- | --- | | | | 商品名 | 首次获批上市时间 | | 2025 年国家医保目录 | | | | | 新纳入 | 芦沃美替尼片 | 复迈宁 | 2025年5月 | | 枸橡酸伏维西利胶囊 | | 复妥宁 | 2025年5月 | | 吡仑帕奈口服混悬液 | | 奥捷宁 ...

微芯生物公告称，2025年12月7日，公司产品西达本胺片（爱谱沙®）纳入《国家医保目录》常规乙类 管理，编号932。医保支付范围包括复发或难治的外周T细胞淋巴瘤等患者。西达本胺是全球首个亚型 选择性组蛋白去乙酰化酶抑制剂，已在多地获批多项适应症。新版《国家医保目录》2026年1月1日起执 行，预计不会对本报告期经营业绩产生重大影响。 ...

东诚药业公告称，其全资子公司安迪科的锝替曲膦注射液被纳入《国家基本医疗保险、生育保险和工伤 保险药品目录（2025年）》。该产品仅用于诊断，可用于药物负荷和静息状态下心肌灌注显像。产品属 乙类注射剂，分类为心血管系统的诊断用放射性药物。《医保目录（2025年）》于2026年1月1日起执 行，暂不会对公司经营业绩构成重大影响。 ...

每经AI快讯，12月7日，众生药业（002317）(002317.SZ)公告称，公司一类创新药物昂拉地韦片(商品 名：安睿威)通过国家医保谈判，首次被纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025 年)》。此外，公司核心产品来瑞特韦片、复方血栓通胶囊、脑栓通胶囊、硫糖铝口服混悬液、羧甲司 坦口服溶液、盐酸氮斯汀滴眼液等继续入选本次《国家医保目录》。 ...

Core Viewpoint - Junshi Biosciences has announced that two of its products, Toripalimab Injection (brand name: Tuoyi®) and Engreztinib Injection (brand name: Junshida®), have been included in the National Medical Insurance Catalog (2025) under the Class B category, effective January 1, 2026 [1] Group 1: Product Developments - Toripalimab has received approval for all 12 indications in mainland China and is the only anti-PD-1 monoclonal antibody in the catalog for treating renal cancer, triple-negative breast cancer, and melanoma [1] - Engreztinib is newly included in the catalog and is the only domestic PCSK9-targeted drug for patients intolerant to statins [1] Group 2: Market Implications - The inclusion of these products in the National Medical Insurance Catalog is expected to enhance their market accessibility and potentially increase sales [1] - With four commercialized products now listed in the National Medical Insurance Catalog, the company is positioned to benefit from broader patient access and reimbursement support [1]

格隆汇12月7日｜康诺亚宣布，公司自主研发的国家1类新药康悦达®（司普奇拜单抗注射液）纳入《国 家基本医疗保险、生育保险和工伤保险药品目录（2025年）》，该目录将自2026年1月1日起正式实施。 此次纳入新版国家基本医疗保险药品目录，康悦达®（司普奇拜单抗）在多个适应症上填补了治疗领域 空白和医保目录空白：它是国产首个治疗中重度特应性皮炎的生物制剂，带来更高治疗获益，打破了长 期以来进口药物的垄断, 为外用药控制不佳的患者带来靶向治疗新选择；同时，它也是国内首个治疗慢 性鼻窦炎伴鼻息肉的生物制剂、全球唯一治疗季节性过敏性鼻炎的IL-4Rα抗体药物，为传统治疗手段效 果不佳、存在未满足临床需求的患者提供了革新性的治疗方案。 ...